CureVac Slumps in Premarket; Tesla, GlaxoSmithKline Rise By Investing.com
[ad_1]
© Reuters Geoffrey Smith
Investing.com — Focus on stocks in premarket trades Tuesday, October 12th. Refresh to receive updates
- TeslaStock rose 1.0% following a defiant slump in Chinese auto sales. The stock posted its highest month of local sales since opening its Shanghai factory. In September, overall Chinese car sales fell by 17% year over year.
- GlaxoSmithKline ADRsThe stock index rose 3.0% following Bloomberg’s report that investors in the consumer health unit of GSK – which will soon be separated from its pharma operations- had attached a valuation of $54 billion to it. GSK also benefited from CureVac’s announcement that they will collaborate on a new messenger RNA-based vaccine to fight Covid-19.
- CureVac(NASDAQ) Stock fell 15% as the company abandoned its efforts to have its first generation drug approved. It had a mere 48% success rate in the prevention of serious diseases, according to clinical tests.
- Chevron Stock in (NYSE) gained 0.1% as the company ignored a shareholder demand to set firm targets for reducing carbon emissions. A company presentation set out goals for the emission the company produces. However, this was a relative reduction, not an absolute, and it did so by presenting them.
- FastenalStock rose 1.0% following the release of quarterly earnings by the Construction Materials Group. The guidance was largely in line to expectations. However, it did warn about rising input prices over the next few months.
- Southwest AirlinesAfter confirming its disruption of the Columbus Day weekend schedule, it was forced to cancel 1,000 more flights on Monday, (NYSE:) stock gained 0.5%. This reversed early losses.
- American AirlinesThe stock of (NASDAQ:) rose 1.0% following it forecasting a smaller loss in the third quarter that many had expected. American anticipates a loss of $620m to $675m, which is lower than the average prediction of $741.7million.
- Signet JewelersThe stock of (NYSE:) rose 4.5% following the announcement that Diamonds Direct will be purchased for $490million in cash.
Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.
Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.
[ad_2]
